Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, E

Global Enzyme Replacement Therapy Market Size study & Forecast, by Product (Agalsidase Beta, Imiglucerase, Velaglucerase Alfa, Idursulfase, Galsulfase, Laronidase, Others) by Disease (Gaucher Disease, Fabry Disease, Pompe Disease, Mucopolysaccharidosis, Exocrine Pancreatic Insufficiency (EPI), Others), by End User (Hospitals, Infusion Centers & Home Healthcare Setting) and Regional Analysis, 2022-2029

Global Enzyme Replacement Therapy Market is valued approximately USD XXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XXX% over the forecast period 2022-2029. The ""enzyme replacement therapy"" refers to a medical procedure that uses human, animal, or recombinantly engineered enzymes to treat congenital enzyme deficiencies. The ERT core principle is the replacement of artificial enzyme in those with an enzyme deficiency. For ERT, the oral and intravenous methods of administration are widely utilized. The key factor driving the market growth is rising prevalence of rare diseases, availability of a wide range of enzyme replacement therapy and rising government initiatives for rare diseases. Thus, create the lucrative demand for the market during forecast period.

The presence of a large patient population suffering from rare lysosomal storage diseases creates high demand for effective treatments such as enzyme replacement therapy. The prevalence of several lysosomal storage disorders such Gaucher, Fabry, Pompe, and MPS is gradually rising on a global level. For instance, according to data released by Cleveland Clinic, in 2020, 6,000 persons in the United States have Gaucher disease, with 95% of them having type 1 Gaucher. A gradual increase in the diagnosis rate of rare diseases is also a result of growing government efforts and non-profit organizations in various nations to raise public awareness. As a result, these key aspects, as well as advantageous reimbursement policies and government support for medical care in developed nations, are increasing the rate of this therapy's adoption and, as a result, propelling the market's expansion over the projection period. Also, rising public awareness about enzyme replacement therapies would create the lucrative opportunities for the market during forecast period. However, the high cost of Enzyme Replacement Therapy stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Enzyme Replacement Therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players and well-developed healthcare infrastructure in the region. Whereas, Asia Pacific is also anticipated to exhibit highest growth rate over the forecast period, owing to factors such as rising number of patients suffering from rare disorders and growing initiatives by other private organizations and the government for the awareness about this therapy would create lucrative growth prospects for the Enzyme Replacement Therapy market across Asia Pacific region.

Major market player included in this report are:
Abbvie Inc.
Astrazeneca Plc
Biomarin Pharmaceutical In
Chiesi Farmaceutici S.P.A.
Digestive Care, Inc.
Leadiant Biosciences, Inc.
Nestle Health Science
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceuticals

Recent Developments in the Market:
 In 2021, Takeda Pharmaceutical Co. Ltd. announced a partnership deal with JCR Pharmaceuticals Co., Ltd., intending to commercialise JR-141 outside the U.S. to treatment of hunter syndrome.
 In 2021, Clinigen Group plc. announced the manufacturing and distribution approval for hunterase ICV throughout Japan to treat patients with Hunter syndrome.


Global Enzyme Replacement Therapy Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Disease, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
The detailed segments and sub-segment of the market are explained below:

By Product:
Agalsidase Beta
Imiglucerase
Velaglucerase Alfa
Idursulfase
Galsulfase
Laronidase
Others
By Disease:
Gaucher Disease
Fabry Disease
Pompe Disease
Mucopolysaccharidosis
Exocrine Pancreatic Insufficiency (EPI)
Others
By End User:
Hospitals
Infusion Centers & Home Healthcare Setting
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Abbvie Inc.
Astrazeneca Plc
Biomarin Pharmaceutical In
Chiesi Farmaceutici S.P.A.
Digestive Care, Inc.
Leadiant Biosciences, Inc.
Nestle Health Science
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceuticals

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.